Disclosed is a pharmaceutical composition including cells committed to the generation of heart tissue, wherein said cells show: i. an observed increase in expression level as compared to a reference of MEF2C and optionally at least one gene further selected from the group consisting of Nkx2.5, Tbx5, GATA4, GATA6, Mesp1, FOG1 FOG2, Flk1 and/or ii. an observed presence of at least one polypeptide species chosen from the group consisting of Nkx2.5, Tbx5, GATA4, GATA6, Mesp1, FOG1 FOG2, Flk1, as compared to a reference and nuclear translocation to the nuclei of the cell of one or more of Nkx2.5 and MEF2C and at least one pharmaceutically acceptable excipient, wherein said at least one pharmaceutically acceptable excipient is a preservation solution, wherein the preservation solution does not contain dimethylsulfoxide (DMSO).
